FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($) |
1 Months Ended | |||||
|---|---|---|---|---|---|---|
Jan. 31, 2024 |
Mar. 31, 2025 |
Dec. 31, 2024 |
Sep. 30, 2024 |
Jan. 08, 2024 |
Dec. 21, 2021 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Estimated fair value of loan agreement | $ 24,300,000 | $ 24,700,000 | ||||
| Warrants exercise price | $ 9.75 | |||||
| Loan and Security Agreement [Member] | ||||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||||
| Warrants to purchase shares | $ 2,400,000 | |||||
| Warrants exercise price | $ 4.07 | $ 4.07 | $ 4.75 | |||
| Shares of common stock issuable upon exercise of warrants | 589,681 | 589,681 |
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|